Pennsaid

Contusions, Pain, Photophobia + 54 more

Treatment

10 FDA approvals

20 Active Studies for Pennsaid

What is Pennsaid

Diclofenac

The Generic name of this drug

Treatment Summary

Diclofenac is an anti-inflammatory medication used to treat pain and inflammation. It is a non-steroidal drug that works by blocking the production of certain enzymes responsible for causing inflammation and pain. Diclofenac is usually prescribed as first line treatment for acute and chronic pain and inflammation. It can be taken alone or in combination with other drugs to prevent ulcers caused by long-term use. Diclofenac was first approved by the FDA in 1988 and is sold under the brand name Voltaren.

Voltaren

is the brand name

image of different drug pills on a surface

Pennsaid Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Voltaren

Diclofenac

1988

767

Approved as Treatment by the FDA

Diclofenac, also called Voltaren, is approved by the FDA for 10 uses including Osteoarthritis of the Knee and Pain .

Osteoarthritis of the Knee

Used to treat Osteoarthritis of the Knee in combination with Capsaicin

Pain

Helps manage Pain

Postoperative Inflammatory Response

Chronic Pain

Helps manage Pain

Osteoarthritis (OA)

Used to treat Osteoarthritis (OA) in combination with Misoprostol

Stomach Ulcer

Used to treat develop NSAID-induced gastric ulcers in combination with Misoprostol

Osteoarthritis of the Knee

Used to treat Osteoarthritis of the Knee in combination with Capsaicin

Osteoarthritis

Used to treat Osteoarthritis (OA) in combination with Misoprostol

Rheumatoid Arthritis

Cataract Surgery

Effectiveness

How Pennsaid Affects Patients

Diclofenac helps to reduce inflammation which in turn reduces pain and fever. However, it can increase the risk of getting an ulcer in the stomach because it reduces the protective mucus that is produced there.

How Pennsaid works in the body

Diclofenac works by stopping the production of molecules called prostaglandins. Prostaglandins increase nerve firing, causing both pain and inflammation. Diclofenac blocks the receptors for these molecules, reducing their effect. It also reduces the body's ability to create a fever, by blocking the receptors that cause heat-generation and heat-loss in the hypothalamus. Finally, it stops T-helper cells from activating and differentiating, which is believed to play a role in arthritis.

When to interrupt dosage

The advised dosage of Pennsaid is contingent upon the diagnosed affliction, including Joint Pain, Postoperative Inflammatory Response and Osteoarthritis (OA). The portion of dosage is contingent upon the technique of delivery (e.g. Cream; Kit; Solution or Kit; Oil; Solution / drops) illustrated in the following table.

Condition

Dosage

Administration

Contusions

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical

Photophobia

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical

Pain

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical

Postoperative

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical

Radiculopathy

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical

Cataract Surgery

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical

Postoperative Pain

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical

Postoperative Inflammatory Response

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical

Rheumatoid Arthritis

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical

Rheumatism

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical

Conjunctivitis

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical

Inflammation

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical

Inflammation

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical

Acute Coryza

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical

Osteoarthritis

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical

radial keratotomy

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical

Pain

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical

Pain

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical

Actinic Keratosis

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical

Arthralgia

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Patch, Patch - Topical, Liquid - Ophthalmic, Tablet, extended release - Oral, Tablet, extended release, Suppository, Rectal, Suppository - Rectal, Solution - Topical, Kit, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical

Warnings

Pennsaid has twenty-nine contraindications, so it must not be taken when encountering any of the conditions mentioned in the following table.

Pennsaid Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Heart failure

Do Not Combine

Crohn's Disease

Do Not Combine

recent history of anal bleeding

Do Not Combine

Hemorrhagic Disorders

Do Not Combine

Gastritis

Do Not Combine

inflammatory lesions of the Rectum

Do Not Combine

active Gastrointestinal Bleeding

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

active Gastrointestinal Perforation

Do Not Combine

Duodenal Ulcer

Do Not Combine

Coronary Artery Bypass Grafting

Do Not Combine

Severe Hepatic Impairment

Do Not Combine

Ulcerative Colitis

Do Not Combine

Liver Diseases

Do Not Combine

Stroke

Do Not Combine

Third trimester of pregnancy

Do Not Combine

Hematochezia

Do Not Combine

Kidney Failure

Do Not Combine

Kidney Failure

Do Not Combine

Anus

Do Not Combine

Ulcer

Do Not Combine

damaged skin

Do Not Combine

Gastric ulcer

Do Not Combine

Peptic Ulcer

Do Not Combine

Hyperkalemia

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Diclofenac may interact with Pulse Frequency

There are 20 known major drug interactions with Pennsaid.

Common Pennsaid Drug Interactions

Drug Name

Risk Level

Description

Brigatinib

Major

The metabolism of Brigatinib can be decreased when combined with Diclofenac.

Cabazitaxel

Major

The metabolism of Cabazitaxel can be decreased when combined with Diclofenac.

Cyclophosphamide

Major

The metabolism of Cyclophosphamide can be decreased when combined with Diclofenac.

Enasidenib

Major

The metabolism of Enasidenib can be decreased when combined with Diclofenac.

Erlotinib

Major

The metabolism of Erlotinib can be decreased when combined with Diclofenac.

Pennsaid Toxicity & Overdose Risk

An overdose of Voltaren may cause symptoms such as fatigue, drowsiness, nausea, vomiting, and stomach pain. In rare cases, high blood pressure, kidney failure, difficulty breathing, or coma may occur. If a Voltaren overdose occurs, supportive care should be provided and vomiting may be induced and activated charcoal administered if the overdose occurred within the last 4 hours.

image of a doctor in a lab doing drug, clinical research

Pennsaid Novel Uses: Which Conditions Have a Clinical Trial Featuring Pennsaid?

At present, 491 active trials are being conducted to investigate the potential of Pennsaid for alleviating Inflammation, Argon Laser Trabeculoplasty and Osteoarthritis of the Knee.

Condition

Clinical Trials

Trial Phases

Inflammation

56 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 3, Phase 4

Osteoarthritis of the Knee

77 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1

Chronic Pain

124 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Phase 3, Early Phase 1, Phase 1

Rheumatoid Arthritis

58 Actively Recruiting

Not Applicable, Phase 3, Phase 2, Phase 1, Phase 4

Postoperative Pain

20 Actively Recruiting

Phase 4, Phase 2, Phase 1, Phase 3, Not Applicable

Dysmenorrhea

1 Actively Recruiting

Not Applicable

Muscle Pain

3 Actively Recruiting

Phase 4, Not Applicable, Phase 2

Conjunctivitis

0 Actively Recruiting

Musculoskeletal System

1 Actively Recruiting

Not Applicable

corneal refractive surgery

0 Actively Recruiting

Postoperative Inflammatory Response

0 Actively Recruiting

Photophobia

3 Actively Recruiting

Not Applicable

Pain

3 Actively Recruiting

Not Applicable

Stomach Ulcer

0 Actively Recruiting

Rheumatism

0 Actively Recruiting

Juvenile arthritis

8 Actively Recruiting

Phase 2, Not Applicable, Phase 3

radial keratotomy

0 Actively Recruiting

Joints

0 Actively Recruiting

Pericarditis

2 Actively Recruiting

Phase 2, Phase 3

Acute Coryza

0 Actively Recruiting

Pennsaid Reviews: What are patients saying about Pennsaid?

5

Patient Review

3/14/2018

Pennsaid for Osteoarthritis of the Knee

I started seeing results after just two weeks of use. The swelling in my right knee went down and I could bear weight on it again. This is a great treatment that I would definitely recommend to others.

5

Patient Review

6/18/2018

Pennsaid for Osteoarthritis of the Knee

I don't usually leave reviews, but I felt compelled to in this case. This treatment has given me more relief than anything else I've tried for my painful knees. I can now walk down stairs normally instead of having to take each step one at a time. It might not work for everyone, but it's definitely worth a shot!

4.7

Patient Review

4/5/2017

Pennsaid for Joint Damage causing Pain and Loss of Function

I found relief for my aching wrists by applying this treatment from my wrist to the end of my thumbs on both hands. I noticed that after about half an hour, it was necessary to wash off the medication and apply eucerin cream to avoid redness and peeling.

2.7

Patient Review

8/30/2021

Pennsaid for Osteoarthritis of the Knee

While this treatment may improve quality of life for some, I found the results to be hardly noticeable. If not for insurance, I wouldn't continue using it given the price point.

2.3

Patient Review

4/19/2017

Pennsaid for Osteoarthritis of the Knee

I have chrondromalsia in both my knees and this medication did nothing to help, despite applying it three times a day. No side effects or relief. Bengay works better. Don't waste your money on this one.

2

Patient Review

6/28/2016

Pennsaid for Joint Damage causing Pain and Loss of Function

I was given a sample of this med for severe joint pain on my knuckles. I have only one hand due to an accident and its difficult to use. i need to use a sponge, it takes a lot of pain away for a while, after use when it dries i wash my hand, does it take the med away what danger does the med have if i dont wash

1.7

Patient Review

4/28/2017

Pennsaid for Osteoarthritis of the Knee

Dr prescribed for knee, worked ok once. Second use the side effects were so horrible (please research) that it left me in pain for weeks. First my knee appeared to have a bad sunburn then it through the process of flaking and peeling off skin. it has been about a month later and I am still itchy all over and still have a red scar covering my knee like a birthmark. The itching has spread all over my body.

1.7

Patient Review

2/14/2018

Pennsaid for Joint Damage causing Pain and Loss of Function

As someone who has had a torn meniscus and bruised tibia, I can say that this medication did not help me at all. In fact, the only times it appeared to work were when I was taking other medications as well.

1.7

Patient Review

12/30/2018

Pennsaid for Joint Damage causing Pain and Loss of Function

I would highly recommend "testing" this product before using it on a larger area of your body. I applied the product to my knee and got an awful rash that lasted for five weeks. It was incredibly painful, itchy, and swollen. I also broke out in hives all over my body which have now been present for four weeks. Needless to say, I will not be using this product again.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about pennsaid

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of Pennsaid?

"or

skin irritation (e.g., dryness, redness, stinging, itching, scaling, hives, swelling), drowsiness, dizziness, nausea, stomach pain, upset stomach, indigestion, or diarrhea."

Answered by AI

What is Pennsaid used to treat?

"Pennsaid is a nonsteroidal anti-inflammatory drug that is applied to the skin. It is used to treat the pain of osteoarthritis of the knee."

Answered by AI

Is Pennsaid same as Voltaren?

"Are Voltaren Gel and Pennsaid the Same Thing? Voltaren Gel and Pennsaid are both topical gel NSAIDs used to treat osteoarthritis pain in the joints, such as the hands and knees."

Answered by AI

How long does it take Pennsaid to start working?

"The full effect of this drug may not be felt for up to two weeks of regular use for certain conditions, like arthritis. If you're only using the drug as needed, keep in mind that pain medications are most effective when taken at the first sign of pain."

Answered by AI

Clinical Trials for Pennsaid

Image of University Center for Ambulatory Surgery in Somerset, United States.

Infusion Pump for Postoperative Pain

18+
All Sexes
Somerset, NJ

This study will be a pragmatic, prospective cluster randomized trial, where clusters will formed based on sequential 2 week time increments across the study recruitment period.. Patients 18 years or older undergoing ACL reconstruction, open shoulder labrum or rotator cuff surgery, arthroscopic rotator cuff repair, proximal or distal patellar realignment surgery, open knee arthrotomy cases (i.e. inside out meniscus repair, osteochondral allograft transplantation (OCA), meniscal allograft transplantation (MAT)) at University Center for Ambulatory Surgery, LLC (UOA) will be reviewed for eligibility. Once identified, potential study subjects will be asked whether they are interested in participating in the project. If the patient agrees, the subject will be given the informed consent to read and sign. Objectives: The primary objective is to compare the effectiveness of postoperative infusion pain pump versus preoperative nerve block in reducing visual analog pain scores/numerical pain rating scale (VAS/NPRS) in the postoperative period. The second objective is to evaluate the requirement of narcotic and non-narcotic analgesic medications between the two groups. Hypotheses: Use of continuous infusion pain pump or single shot peripheral block will result in similar post-operative pain control after outpatient sports medicine surgical cases.

Phase 4
Recruiting

University Center for Ambulatory Surgery

Image of Montana State University in Bozeman, United States.

Haskap Berries for Exercise Performance Recovery

18 - 35
All Sexes
Bozeman, MT

The purpose of this clinical trial is to determine how certain food items affect oxidative stress, inflammation, and performance recovery from exercise induced muscle damage in a resistance trained population. The main questions The investigators aim to answer are the following: * Do Haskaps speed the recovery of oxidative stress and inflammation markers after an intense lower body workout in resistance trained adults? * Do Haskaps speed the recovery of performance measures after an intense lower body workout in resistance trained adults? * The data collected in this investigation may also be used to ask additional questions not yet identified. For example, the investigators may use the stored samples to evaluate how the blood metabolites of participants differ before and after intense exercise. These additional questions are called secondary analyses. Please note that no genetic analysis will be conducted and racial and ethnic differences among participants will not be used in any secondary analyses. Researches will compare Haskap juice to a color, flavor and carbohydrate matched placebo to see if Haskaps speed recovery in inflammation, oxidative stress and performance. * Participants will be asked to drink either Haskap juice or placebo and follow a low polyphenolic diet * Participants will perform an intense resistance workout * Participants will have their blood drawn before and after the workout * Performance will be analyzed at 24, 48 and 72 hours after the workout

Recruiting
Paid Trial

Montana State University

Mary P Miles

Image of University of North Carolina at Chapel Hill in Chapel Hill, United States.

Pain Medicines for Period Pain in Crohn's Disease

18 - 44
Female
Chapel Hill, NC

The purpose of this pilot study is to prepare for a larger study that will compare the effectiveness and safety of two common pain medications, ibuprofen and acetaminophen, to help treat period cramps in women with Crohn's disease. The goal of this study is to identify any challenges in running a larger study. The investigators will track how many people sign up for the study, how well participants follow the study plan, how many people stay in the study, and whether they are able to complete all the study activities, such as taking the medication, submitting samples, and filling out surveys. During the study, participants will undergo a screening visit that includes a blood draw, physical exam, pregnancy test, stool testing, and complete surveys about Crohn's disease and menstrual cycles. Once this visit is complete, the rest of the study will occur at home. Participants will be assigned to take either ibuprofen or acetaminophen to help treat period cramps for four menstrual cycles in a row. Participants will take ibuprofen for two cycles and acetaminophen for two cycles. Participants will know which medication is being taken at any given time, but the order in which they take the medications will be randomly assigned. Before each menstrual cycle, participants will submit a stool sample and fill out a short (\<1 minute) electronic survey. When participants develop period cramps, they will take the assigned medication for three days and fill out short (\<1 minute) electronic surveys about their cramps. After participants finish taking the medication for three days, they will submit another stool sample and fill out two more short (\<1 minute) electronic surveys. After have completing this process for four menstrual cycles, a remote interview with a researcher to give feedback on the study will be conducted.

Waitlist Available
Has No Placebo

University of North Carolina at Chapel Hill

Erica J Brenner, MD, MSCR

Image of AltaSciences, Inc in Cypress, United States.

SBS-147 Safety Study

18 - 55
All Sexes
Cypress, CA

This study is part of the HEAL Initiative supported by the NIH. The purpose of this study is to learn how safe the study drug, SBS-147, is and how people's bodies respond to and process it. Researchers will also look for any side effects that may occur when taking SBS-147. Some participants will receive SBS-147, and others will receive a placebo, which looks the same but does not contain any medicine. This helps researchers fairly compare results. The study includes two parts: Single-Dose Group, where Participants receive SBS-147 or placebo one time. Multiple-Dose Group, where Participants receive SBS-147 or placebo once or twice daily for 7 days.

Phase 1
Waitlist Available

AltaSciences, Inc

Jeff Reich, MD

Sparian Biosciences, Inc

Have you considered Pennsaid clinical trials?

We made a collection of clinical trials featuring Pennsaid, we think they might fit your search criteria.
Go to Trials
Image of Byers Eye Institute in Palo Alto, United States.

LLM-Based Education for Cataract Surgery

18+
All Sexes
Palo Alto, CA

Patients with cataracts disease need to choose what type of artificial lens will go into their eye prior to surgery date. Some lenses are standard and are usually covered by insurance. Other "premium" lenses have various benefits such as reducing the need for glasses but usually require out-of-pocket costs. The combined busy outpatient clinic and complexity of artificial lens choices in the ever-changing world of cataract surgery tends to lead patients confused about their available lens options. There is an abundance of educational material present in premium lenses, however these are limited by accessibility and are standardized at single educational levels. Therefore in the present study, we want to test whether giving patients a short LLM powered AI-guided explanation from Custom GPT from OpenAI of lens options prior to their consultation with their doctor can improve visit efficiency, physician explanation and patient understanding of lens options. We will compare two groups: standard of care versus standard of care plus AI education. The LLM in this study is intended to provide supplemental information about premium intraocular lens(IOLs) options to study participants, and is no means supposed to replace a health care professional in the diagnosis, cure, treatment, and/or mitigation of disease. Study is analogous to giving a verified health pamphlet to a patient for them to view and learn different IOL options, in other words, facilitating patient understanding of their options. The LLM will be trained by several health care professionals and MD specialists to provide sufficient instructions. Sources will include verified online resources and MD information. The investigators hope to learn if a large language model-based educational tool can improve visit efficiency, physician explanation and patient understanding of intraocular lens options. New knowledge of this study could guide how cataract counseling is delivered in the future and may help clinics spend more time on individualized questions instead of repeating generic information.

Waitlist Available
Has No Placebo

Byers Eye Institute

Robert T Chang, MD

Image of University of New Brunswick in Fredericton, Canada.

Mediterranean Diet for Toddler Health

24 - 36
All Sexes
Fredericton, Canada

Toddlerhood (ages 2-3) is a critical window when the gut microbiome is still developing and eating habits are being established. Yet, many Canadian toddlers eat diets high in sugar and salt, which may affect long-term health. This study will test whether a MED diet can improve dietary inflammation, gut health, and body composition in toddlers and whether a tailored nutrition education program for parents can help families maintain healthy eating patterns. In this study, toddlers will be randomly assigned to a 3-week MED diet or their usual diet. Families in the MED diet group will receive free meal boxes for the 3 weeks, plus guidance from a nutrition researcher through a structured education program. The standard diet group will continue their regular diet with general nutrition advice. Researchers will collect dietary information, body composition assessments, and stool samples to measure gut microbiome composition and metabolites. This first study of a controlled diet intervention in toddlers, combining behavioral support, high-quality food provision, and advanced gut microbiome analysis, will help understand how early diet shapes lifelong eating habits and health, guiding public health strategies and precision nutrition approaches to prevent chronic disease from early life.

Waitlist Available
Has No Placebo

University of New Brunswick

Dr. Maryam Kebbe, PhD, CLC

Have you considered Pennsaid clinical trials?

We made a collection of clinical trials featuring Pennsaid, we think they might fit your search criteria.
Go to Trials

Have you considered Pennsaid clinical trials?

We made a collection of clinical trials featuring Pennsaid, we think they might fit your search criteria.
Go to Trials